U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C19H25N5O4
Molecular Weight 387.4329
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TERAZOSIN

SMILES

COC1=CC2=NC(=NC(N)=C2C=C1OC)N3CCN(CC3)C(=O)C4CCCO4

InChI

InChIKey=VCKUSRYTPJJLNI-UHFFFAOYSA-N
InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22)

HIDE SMILES / InChI

Molecular Formula C19H25N5O4
Molecular Weight 387.4329
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/10503165

Terazosin (marketed as Hytrin or Zayasel) is a selective alpha1-antagonist used for treatment of symptoms of benign prostatic hyperplasia (BPH). It also acts to lower blood pressure, so it is a drug of choice for men with hypertension and prostate enlargement. All three receptor subtypes appear to be involved in maintaining vascular tone. The α1A-receptor maintains basal vascular tone while the α1B-receptor mediates the vasocontrictory effects of exogenous α1-agonists. Activation of α1-receptors activates Gq-proteins, which results in intracellular stimulation of phospholipases C, A2, and D. This results in mobilization of Ca2+ from intracellular stores, activation of mitogen-activated kinase and PI3 kinase pathways and subsequent vasoconstriction.

CNS Activity

Curator's Comment: Known to be CNS penetrant in rats Human data not available

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
TERAZOSIN HYDROCHLORIDE

Approved Use

are used to treat high blood preassure (hypertension); are also used to treat benign prostatic hyperplasia (BPH) in men

Launch Date

9.5022717E11
Primary
TERAZOSIN HYDROCHLORIDE

Approved Use

are used to treat high blood preassure (hypertension); are also used to treat benign prostatic hyperplasia (BPH) in men

Launch Date

9.501408E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
48 ng/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERAZOSIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
37 ng/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERAZOSIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
408 ng × h/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERAZOSIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
418 ng × h/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERAZOSIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8.4 h
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERAZOSIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
9.5 h
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERAZOSIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
8%
TERAZOSIN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
80 mg 1 times / day multiple, oral
Highest studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1169
unhealthy
n = 14
Health Status: unhealthy
Condition: Hypertension
Population Size: 14
Sources: Page: p.1169
Disc. AE: Dizziness...
AEs leading to
discontinuation/dose reduction:
Dizziness
Sources: Page: p.1169
80 mg 1 times / day multiple, oral
Highest studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.903
unhealthy
n = 37
Health Status: unhealthy
Condition: Hypertension
Population Size: 37
Sources: Page: p.903
Disc. AE: Syncope...
AEs leading to
discontinuation/dose reduction:
Syncope (2.7%)
Sources: Page: p.903
20 mg 1 times / day multiple, oral
MTD
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.9
unhealthy
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia|Hypertension
Sources: Page: p.9
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia|Hypertension
Sources: Page: p.6
Other AEs: Syncope, Postural hypotension...
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.409
unhealthy
n = 494
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 494
Sources: Page: p.409
Disc. AE: Dizziness, Asthenia...
AEs leading to
discontinuation/dose reduction:
Dizziness (6.7%)
Asthenia (3.8%)
Somnolence (2%)
Chest pain (1.6%)
Headache (1.2%)
Dyspnea (1.2%)
Prostate carcinoma (1%)
Sources: Page: p.409
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Disc. AE: Fever, Headache...
AEs leading to
discontinuation/dose reduction:
Fever (0.5%)
Headache (1.1%)
Postural hypotension (0.5%)
Syncope (0.5%)
Nausea (0.5%)
Dizziness (2%)
Vertigo (0.5%)
Dyspnea (0.5%)
Blurred vision (0.6%)
Amblyopia (0.6%)
Urinary tract infection (0.5%)
Sources: Page: p.12
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Disc. AE: Asthenia, Headache...
AEs leading to
discontinuation/dose reduction:
Asthenia (1.6%)
Headache (1.3%)
Palpitations (1.4%)
Postural hypotension (0.5%)
Syncope (0.5%)
Tachycardia (0.6%)
Nausea (0.8%)
Peripheral edema (0.6%)
Dizziness (3.1%)
Paresthesia (0.8%)
Somnolence (0.6%)
Dyspnea (0.9%)
Nasal congestion (0.6%)
Blurred vision (0.6%)
Sources: Page: p.16
AEs

AEs

AESignificanceDosePopulation
Dizziness Disc. AE
80 mg 1 times / day multiple, oral
Highest studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1169
unhealthy
n = 14
Health Status: unhealthy
Condition: Hypertension
Population Size: 14
Sources: Page: p.1169
Syncope 2.7%
Disc. AE
80 mg 1 times / day multiple, oral
Highest studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.903
unhealthy
n = 37
Health Status: unhealthy
Condition: Hypertension
Population Size: 37
Sources: Page: p.903
Postural hypotension
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia|Hypertension
Sources: Page: p.6
Priapism
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia|Hypertension
Sources: Page: p.6
Syncope
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia|Hypertension
Sources: Page: p.6
Prostate carcinoma 1%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.409
unhealthy
n = 494
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 494
Sources: Page: p.409
Dyspnea 1.2%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.409
unhealthy
n = 494
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 494
Sources: Page: p.409
Headache 1.2%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.409
unhealthy
n = 494
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 494
Sources: Page: p.409
Chest pain 1.6%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.409
unhealthy
n = 494
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 494
Sources: Page: p.409
Somnolence 2%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.409
unhealthy
n = 494
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 494
Sources: Page: p.409
Asthenia 3.8%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.409
unhealthy
n = 494
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 494
Sources: Page: p.409
Dizziness 6.7%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.409
unhealthy
n = 494
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 494
Sources: Page: p.409
Dyspnea 0.5%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Fever 0.5%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Nausea 0.5%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Postural hypotension 0.5%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Syncope 0.5%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Urinary tract infection 0.5%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Vertigo 0.5%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Amblyopia 0.6%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Blurred vision 0.6%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Headache 1.1%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Dizziness 2%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Postural hypotension 0.5%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Syncope 0.5%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Blurred vision 0.6%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Nasal congestion 0.6%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Peripheral edema 0.6%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Somnolence 0.6%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Tachycardia 0.6%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Nausea 0.8%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Paresthesia 0.8%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Dyspnea 0.9%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Headache 1.3%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Palpitations 1.4%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Asthenia 1.6%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Dizziness 3.1%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
1998
Lower urinary tract symptoms suggestive of benign prostatic obstruction--Triumph: the role of general practice databases.
2001
The short-term effects of terazosin in Japanese men with benign prostatic hyperplasia.
2001 Apr
[A randomized comparative study assessing once versus twice a day treatment of benign prostatic hyperplasia with terazosin].
2001 Feb
Magnetic resonance imaging and morphometric histologic analysis of prostate tissue composition in predicting the clinical outcome of terazosin therapy in benign prostatic hyperplasia.
2001 Feb
Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia.
2001 Jun 7
Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study.
2001 May
Evaluating adverse cardiovascular effects of drug treatment for benign prostatic hyperplasia (BPH): methodological considerations.
2001 May
[Treatment of external RF hyperthermia combining with alpha 1-adrenergic receptor blocker for patients with prostatodynia and chronic non-bacterial prostatitis].
2002
Tamsulosin: an update of its role in the management of lower urinary tract symptoms.
2002
Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials.
2002 Dec 12
Modeling of relationships between pharmacokinetics and blockade of agonist-induced elevation of intraurethral pressure and mean arterial pressure in conscious dogs treated with alpha(1)-adrenoceptor antagonists.
2002 Feb
Effect of fiduxosin, an antagonist selective for alpha(1A)- and alpha(1D)-adrenoceptors, on intraurethral and arterial pressure responses in conscious dogs.
2002 Feb
Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action.
2002 Jan 15
Prior iontophoresis of saline enhances vasoconstriction to phenylephrine and clonidine in the skin of the human forearm.
2002 Jul
Characterization of some novel alpha 1-adrenoceptor antagonists in human hyperplastic prostate.
2002 Jun 7
Mice expressing the alpha(1B)-adrenergic receptor induces a synucleinopathy with excessive tyrosine nitration but decreased phosphorylation.
2002 Nov
[Serum nitric oxide and D-dimer before and after administering antihypertensive drugs in essential hypertension].
2003 Aug
The role of combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia.
2003 Aug
Immobility from administration of the alpha1-adrenergic antagonist, terazosin, in the IVth ventricle in rats.
2003 Dec 26
Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial.
2003 Feb
Alpha 1-adrenoceptor effects mediated by protein kinase C alpha in human cultured prostatic stromal cells.
2003 Jan
[Results of treatment of irritative symptoms and urinary retention in patients 1 year after radical retropubic prostatectomy].
2003 Jan-Feb
Comparison of finasteride and alpha-blockers as independent risk factors for erectile dysfunction.
2003 Jul-Aug
The ICH guidance in practice: stress decomposition studies on three piperazinyl quinazoline adrenergic receptor-blocking agents and comparison of their degradation behaviour.
2003 Mar 26
Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction.
2003 May 19
Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia.
2003 Nov
Hormonal and morphologic evaluation of the effects of antiandrogens on the blood supply of the rat prostate.
2003 Nov
[Pharmacologic treatment of benign prostatic hyperplasia].
2003 Sep 14
The alpha1-adrenoceptor antagonist terazosin induces prostate cancer cell death through a p53 and Rb independent pathway.
2003 Sep-Oct
Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs).
2004 Feb 23
Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia.
2004 Mar
Patents

Sample Use Guides

In Vivo Use Guide
for Hypertension: Initial dose: 1 mg orally once a day at bedtime; Maintenance dose: 1-5 mg orally once a day. Maximum dose: 20 mg per day. Usual Adult Dose for Benign Prostatic Hyperplasia: Initial dose: 1 mg orally once a day at bedtime. Maintenance dose: Increased in a stepwise fashion to 2 mg, 5 mg, or 10 mg once a day to achieve desired improvement of symptoms.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: TZ (terazosin) has a new protein target, Pgk1 (phosphoglycerate kinase 1), and reveal its corresponding biological effect. As a clinical drug, TZ may be quickly translated into treatments for diseases including stroke and sepsis.
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 16 19:26:32 UTC 2022
Edited
by admin
on Fri Dec 16 19:26:32 UTC 2022
Record UNII
8L5014XET7
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TERAZOSIN
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
Terazosin [WHO-DD]
Common Name English
TERAZOSIN [MI]
Common Name English
terazosin [INN]
Common Name English
TERAZOCIN
Systematic Name English
TERAZOSABB
Brand Name English
TERAZOSIN [VANDF]
Common Name English
Classification Tree Code System Code
WHO-VATC QG04CA03
Created by admin on Fri Dec 16 19:26:32 UTC 2022 , Edited by admin on Fri Dec 16 19:26:32 UTC 2022
WHO-ATC G04CA03
Created by admin on Fri Dec 16 19:26:32 UTC 2022 , Edited by admin on Fri Dec 16 19:26:32 UTC 2022
NDF-RT N0000000099
Created by admin on Fri Dec 16 19:26:32 UTC 2022 , Edited by admin on Fri Dec 16 19:26:32 UTC 2022
LIVERTOX NBK548096
Created by admin on Fri Dec 16 19:26:32 UTC 2022 , Edited by admin on Fri Dec 16 19:26:32 UTC 2022
NDF-RT N0000175553
Created by admin on Fri Dec 16 19:26:32 UTC 2022 , Edited by admin on Fri Dec 16 19:26:32 UTC 2022
NCI_THESAURUS C29713
Created by admin on Fri Dec 16 19:26:32 UTC 2022 , Edited by admin on Fri Dec 16 19:26:32 UTC 2022
Code System Code Type Description
RXCUI
37798
Created by admin on Fri Dec 16 19:26:32 UTC 2022 , Edited by admin on Fri Dec 16 19:26:32 UTC 2022
PRIMARY RxNorm
IUPHAR
7302
Created by admin on Fri Dec 16 19:26:32 UTC 2022 , Edited by admin on Fri Dec 16 19:26:32 UTC 2022
PRIMARY
DRUG CENTRAL
3584
Created by admin on Fri Dec 16 19:26:32 UTC 2022 , Edited by admin on Fri Dec 16 19:26:32 UTC 2022
PRIMARY
CHEBI
9445
Created by admin on Fri Dec 16 19:26:32 UTC 2022 , Edited by admin on Fri Dec 16 19:26:32 UTC 2022
PRIMARY
ChEMBL
CHEMBL611
Created by admin on Fri Dec 16 19:26:32 UTC 2022 , Edited by admin on Fri Dec 16 19:26:32 UTC 2022
PRIMARY
DAILYMED
8L5014XET7
Created by admin on Fri Dec 16 19:26:32 UTC 2022 , Edited by admin on Fri Dec 16 19:26:32 UTC 2022
PRIMARY
DRUG BANK
DB01162
Created by admin on Fri Dec 16 19:26:32 UTC 2022 , Edited by admin on Fri Dec 16 19:26:32 UTC 2022
PRIMARY
NCI_THESAURUS
C61964
Created by admin on Fri Dec 16 19:26:32 UTC 2022 , Edited by admin on Fri Dec 16 19:26:32 UTC 2022
PRIMARY
INN
4843
Created by admin on Fri Dec 16 19:26:32 UTC 2022 , Edited by admin on Fri Dec 16 19:26:32 UTC 2022
PRIMARY
EPA CompTox
DTXSID3023639
Created by admin on Fri Dec 16 19:26:32 UTC 2022 , Edited by admin on Fri Dec 16 19:26:32 UTC 2022
PRIMARY
MESH
C041226
Created by admin on Fri Dec 16 19:26:32 UTC 2022 , Edited by admin on Fri Dec 16 19:26:32 UTC 2022
PRIMARY
EVMPD
SUB10907MIG
Created by admin on Fri Dec 16 19:26:32 UTC 2022 , Edited by admin on Fri Dec 16 19:26:32 UTC 2022
PRIMARY
FDA UNII
8L5014XET7
Created by admin on Fri Dec 16 19:26:32 UTC 2022 , Edited by admin on Fri Dec 16 19:26:32 UTC 2022
PRIMARY
PUBCHEM
5401
Created by admin on Fri Dec 16 19:26:32 UTC 2022 , Edited by admin on Fri Dec 16 19:26:32 UTC 2022
PRIMARY
MERCK INDEX
M10567
Created by admin on Fri Dec 16 19:26:32 UTC 2022 , Edited by admin on Fri Dec 16 19:26:32 UTC 2022
PRIMARY Merck Index
WIKIPEDIA
TERAZOSIN
Created by admin on Fri Dec 16 19:26:32 UTC 2022 , Edited by admin on Fri Dec 16 19:26:32 UTC 2022
PRIMARY
CAS
63590-64-7
Created by admin on Fri Dec 16 19:26:32 UTC 2022 , Edited by admin on Fri Dec 16 19:26:32 UTC 2022
PRIMARY
LACTMED
Terazosin
Created by admin on Fri Dec 16 19:26:32 UTC 2022 , Edited by admin on Fri Dec 16 19:26:32 UTC 2022
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
TARGET -> INHIBITOR
BINDER->LIGAND
BINDING
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
URINE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC